Literature DB >> 8980928

Interspecies scaling: predicting clearance of anticancer drugs in humans. A comparative study of three different approaches using body weight or body surface area.

I Mahmood1.   

Abstract

From this study it is proposed that the clearance of anti-cancer drugs may be best estimated if they follow the following trend: (i) that if the exponent of the allometric equation (clearance vs body weight) lies between 0.55-0.75 (0.75 was chosen after Kleiber's power rule (18)), then a simple allometric equation can predict the clearance reasonably well; (ii) if the exponent of the allometric equation lies between 0.75 to approximately 0.90, clearance can be reasonably predicted using CL x MLP; and (iii) if the exponent of the allometric equation is > or = 0.90, the clearance can be predicted using the product of clearance and brain weight.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980928     DOI: 10.1007/BF03189726

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  13 in total

Review 1.  Extrapolation of animal toxicity to humans: interspecies comparisons in drug development.

Authors:  E M Voisin; M Ruthsatz; J M Collins; P C Hoyle
Journal:  Regul Toxicol Pharmacol       Date:  1990-10       Impact factor: 3.271

2.  Animal scale-up.

Authors:  R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

Review 3.  What does the power function reveal about structure and function in animals of different size?

Authors:  A A Heusner
Journal:  Annu Rev Physiol       Date:  1987       Impact factor: 19.318

Review 4.  Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.

Authors:  H Boxenbaum
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

5.  Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.

Authors:  H Boxenbaum
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

6.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

7.  Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species.

Authors:  R L Dedrick; D D Forrester; J N Cannon; S M el-Dareer; L B Mellett
Journal:  Biochem Pharmacol       Date:  1973-10-01       Impact factor: 5.858

8.  Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.

Authors:  J W Paxton; S N Kim; L R Whitfield
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

9.  Interspecies comparison of acivicin pharmacokinetics.

Authors:  J P McGovren; M G Williams; J C Stewart
Journal:  Drug Metab Dispos       Date:  1988 Jan-Feb       Impact factor: 3.922

Review 10.  Pharmacokinetics and early clinical studies of selected new drugs.

Authors:  S B Kaye; P Workman; M A Graham; J Cassidy; D Jodrell
Journal:  Cancer Surv       Date:  1993
View more
  5 in total

Review 1.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

2.  Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics.

Authors:  M R Feng; X Lou; R R Brown; A Hutchaleelaha
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

3.  Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice.

Authors:  David J Feola; Beth A Garvy
Journal:  Clin Vaccine Immunol       Date:  2006-02

Review 4.  Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems.

Authors:  Joseph A Piscatelli; Jisun Ban; Andrew T Lucas; William C Zamboni
Journal:  Pharmaceutics       Date:  2021-01-17       Impact factor: 6.321

Review 5.  Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.

Authors:  Eva Germovsek; Ming Cheng; Craig Giragossian
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.